Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [330]
News [1860]
Articles [57]
Editorials [3]
Conferences [62]
elearning [13]
Molecular imaging using PET-CT and personalised therapy with neuroendocrine...
Dr Harshad Kulkarni - Zentralklinik, Bad Berka, Germany
Molecular imaging using PET-CT and personalised therapy with neuroendocrine tumours ( Dr Harshad Kulkarni - Zentralklinik, Bad Berka, Germany )
12 Nov 2013
The immune microenvironment as an anti-cancer therapeutic strategy
Dr Lisa Coussens - Oregon Science & Health University, USA
The immune microenvironment as an anti-cancer therapeutic strategy ( Dr Lisa Coussens - Oregon Science & Health University, USA )
12 Nov 2013
SBRT in tumours of the spinal column
Dr Peter Gerszten - University of Pittsburgh, USA
SBRT in tumours of the spinal column ( Dr Peter Gerszten - University of Pittsburgh, USA )
15 Aug 2013
Editor’s Choice - ecancermedicalscience August 2013
Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy
Editor’s Choice - ecancermedicalscience August 2013 ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )
8 Aug 2013
ECC 2013 Preview: Scientific programme highlights
Prof Vincenzo Valentini and Ian Banks
ECC 2013 Preview: Scientific programme highlights ( Prof Vincenzo Valentini and Ian Banks )
11 Jul 2013
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives...
Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
Adding bevacizumab to standard first-line chemoradiation for glioblastoma gives no survival benefit ( Prof Mark Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
6 Jun 2013
Science behind phase I clinical trials: targeting tumour cell development...
Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA
Science behind phase I clinical trials: targeting tumour cell development pathways ( Dr Gary K. Schwartz - Memorial Sloan-Kettering Cancer Center, New York, USA )
6 Jun 2013
No survival benefit to adding bevacizumab to standard first-line chemoradiation...
Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA
No survival benefit to adding bevacizumab to standard first-line chemoradiation for glioblastoma ( Dr Mark R. Gilbert - University of Texas MD Anderson Cancer Center, Houston, USA )
2 Jun 2013
Improving outcomes of childhood neuroblastoma
Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia...
Improving outcomes of childhood neuroblastoma ( Dr Garrett Brodeur - Cancer Center at The Children’s Hospital of Philadelphia, USA )
1 Jun 2013
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours
Dr Matthew Murray - Cambridge Cancer Centre, UK
Profiles of malignant GCTs and potential biomarkers for CNS germ cell tumours ( Dr Matthew Murray - Cambridge Cancer Centre, UK )
29 May 2013
Epidemiology of central nervous system germ cell tumours
Dr Eric Bouffet - The Hospital for Sick Children, Ontario, Canada
Epidemiology of central nervous system germ cell tumours ( Dr Eric Bouffet - The Hospital for Sick Children, Ontario, Canada )
29 May 2013
Possible consequences and potential for improvement for time of diagnosis for...
Dr Juliet Hale - Newcastle University, UK
Possible consequences and potential for improvement for time of diagnosis for intracranial germ cell tumours ( Dr Juliet Hale - Newcastle University, UK )
29 May 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation